Albireo Pharma Inc (NASDAQ:ALBO)
| 36.75 Delayed Data As of 4:00pm ET |  -0.09 / -0.24%Today’s Change | 11.26 Today|||52-Week Range 49.00 | -2.03% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $723.6M |
Company Description
Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
Contact Information
Albireo Pharma, Inc. 10 Post Office Square Boston Massachusetts 02109 |
Employees
Shareholders
| Other institutional | 50.73% |
| Mutual fund holders | 40.90% |
| Individual stakeholders | 21.52% |
Top Executives
| Ronald H. W. Cooper | President, Chief Executive Officer & Director |
| Simon John Harford | Chief Financial Officer & Treasurer |
| Jan Peter Mattsson | Chief Scientific Officer, Managing Director-Sweden |
| Patrick Taylor Horn | Chief Medical Officer |
| Per-Göran Gillberg | Vice President-Development & Owner |
